Skip to content Skip to sidebar Skip to footer

Revolutionizing Maternal Healthcare: APT-Sepsis Program Reduces Maternal Infections and Deaths

A groundbreaking clinical trial has unveiled a structured, sustainable methodology that significantly reduces maternal infections and deaths, underpinning a new strategy in infection prevention and treatment. This program, known as the Active Prevention and Treatment of Maternal Sepsis (APT-Sepsis), was collaboratively developed by researchers at the University of Liverpool, the World Health Organization (WHO), and…

Read more

LPOXY Therapeutics Secures Funding for Innovative Approach to Preventing C. difficile Infections

LPOXY Therapeutics, a pioneering biopharmaceutical corporation in the clinical development phase, is making notable strides in developing a preventive method for Clostridioides difficile infections that does not involve antibiotics. The company recently signed an agreement with 5Horizons Ventures, a recognized venture capital firm specializing in life sciences, with a proven track record of supporting revolutionary…

Read more

The Link Between Gut Microbiome Shifts and Improved Mental Health Outcomes: A Dive into Recent Phase 3 Clinical Trial Data

The Digestive Disease Week conference in San Diego unveiled compelling new analysis from a recent Phase 3 clinical trial. The findings suggest that a live biotherapeutic, primarily used to prevent the recurrence of Clostridioides difficile infection, may also enhance mental health parameters, creating a significant correlation with alterations in the gut's microbiome and metabolome. Patients…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]